HanAll Biopharma Stock Surges 30% on Immunovant Clinical Trial Results
HanAll Biopharma's stock rose by its daily limit on May 21st, driven by positive interim clinical trial results for a new drug candidate from its global partner, Immunovant.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 8+/10 (~1-3 per day, no spam). Verified 30d hit rate 51.8%.
Get high-impact news instantly
Top stories with score 8/10+ delivered to your Telegram in real time. Free.
Join Telegram channel